<DOC>
	<DOCNO>NCT01307397</DOCNO>
	<brief_summary>This open-label , multicenter study evaluate safety efficacy RO5185426 patient BRAF V600 mutation-positive , surgically incurable unresectable stage IIIC IV metastatic melanoma . Eligible patient receive RO5185426 ( 960 mg twice daily orally ) disease progression unacceptable toxicity occur , safety follow-up 24 month discontinuation study drug .</brief_summary>
	<brief_title>A Study RO5185426 Patients With Metastatic Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<criteria>Adult patient , &gt; /= 16 year age Histologically confirm metastatic melanoma ( surgically incurable unresectable stage IIIC stage IV ; AJCC ) BRAF V600 mutation determine Cobas 4800 BRAF Mutation Test Patients may may receive prior systemic therapy metastatic melanoma Eastern Cooperative Oncology Group ( ECOG ) performance status 02 Adequate hematologic , renal liver function Evidence symptomatic CNS lesion , use steroid antiseizure medication treatment brain metastasis prior first administration RO5185426 Previous malignancy ( melanoma ) within past 2 year , except treat control basal squamous cell carcinoma skin carcinoma insitu cervix Concurrent administration anticancer therapy administer study Clinically significant cardiovascular disease event within 6 month prior first administration study drug Refractory nausea vomiting , external biliary shunt , significant bowel resection would preclude adequate absorption</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>